MARKET

PYPD

PYPD

PolyPid Ltd.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

14.00
+0.02
+0.14%
Closed 16:00 08/03 EDT
OPEN
15.25
PREV CLOSE
13.98
HIGH
15.25
LOW
13.99
VOLUME
17.06K
TURNOVER
--
52 WEEK HIGH
19.45
52 WEEK LOW
13.35
MARKET CAP
229.90M
P/E (TTM)
-20.6734
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average PYPD stock price target is 25.00 with a high estimate of 30.00 and a low estimate of 22.00.

EPS

PYPD News

More
PolyPid Granted Fast Track Designation from FDA for D-PLEX for Prevention of Surgical Site Infections in Abdominal Surgery
Benzinga · 15h ago
PolyPid Granted Fast Track Designation from FDA for D-PLEX₁₀₀ for Prevention of Surgical Site Infections in Abdominal Surgery
PETAH TIKVA, Israel, Aug. 03, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology
GlobeNewswire · 15h ago
PolyPid to Present Phase 2 Results of D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal Surgery at the American Society of Colon and Rectal Surgeons 2020 Annual Scientific Conference Recorded Sessions
PETAH TIKVA, Israel, July 27, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology
GlobeNewswire · 07/27 11:00
Raymond James Initiates Coverage On PolyPid with Outperform Rating, Announces Price Target of $23
Raymond James initiates coverage on PolyPid (NASDAQ:PYPD) with a Outperform rating and announces Price Target of $23.
Benzinga · 07/21 12:19
PolyPid started at outperform with $23 stock price target at Raymond James
marketwatch.com · 07/21 07:48
The Week Ahead In Biotech: Jazz Awaits FDA Nod For Sleep Disorder Drug, Earnings Trickle In, ACell IPO
Biotech stocks advanced in the week ended July 17 thanks to positive broader market sentiment, encouraging news flow on the COVID-19 front and fairly positive results reported by pharma giant Johnson & Johnson (NYSE: JNJ).
Benzinga · 07/19 19:11
The Daily Biotech Pulse: Ziopharm Starts Blood Cancer Study, Allergan's Botox Gets Label Expansion, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 9) Affimed NV (NASDAQ: AFMD)
Benzinga · 07/10 11:25
The Daily Biotech Pulse: FDA Nod For Osmotica, OptiNose Strikes Co-promotion Deal, Orphan Drug Designation For AnaptysBio
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8)
Benzinga · 07/09 12:09

Industry

Pharmaceuticals
+1.31%
Pharmaceuticals & Medical Research
+2.05%

Hot Stocks

Symbol
Price
%Change

About PYPD

Polypid Ltd is a biopharmaceutical company at the clinical stage, based in Israel . The company focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.
More

Webull offers kinds of Polypid Ltd stock information, including NASDAQ:PYPD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PYPD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PYPD stock methods without spending real money on the virtual paper trading platform.